Advertisement

Loading...

EvoNext Holdings S.A.

EVE.SWSIX
Healthcare
Biotechnology
CHF0.83
CHF-0.08(-8.79%)
Swiss Market opens in 0h 25m

EvoNext Holdings S.A. Fundamental Analysis

EvoNext Holdings S.A. (EVE.SW) shows weak financial fundamentals with a PE ratio of -7.04, profit margin of 0.00%, and ROE of -13.27%. The company generates N/A in annual revenue with weak year-over-year growth of -1.00%.

Key Strengths

Cash Position105.29%
PEG Ratio0.04
Current Ratio8.34

Areas of Concern

ROE-13.27%
Operating Margin0.00%
We analyze EVE.SW's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -83.5/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-83.5/100

We analyze EVE.SW's fundamental strength across five key dimensions:

Efficiency Score

Weak

EVE.SW struggles to generate sufficient returns from assets.

ROA > 10%
-12.01%

Valuation Score

Excellent

EVE.SW trades at attractive valuation levels.

PE < 25
-7.04
PEG Ratio < 2
0.04

Growth Score

Weak

EVE.SW faces weak or negative growth trends.

Revenue Growth > 5%
-1.00%
EPS Growth > 10%
1.01%

Financial Health Score

Excellent

EVE.SW maintains a strong and stable balance sheet.

Debt/Equity < 1
0.00
Current Ratio > 1
8.34

Profitability Score

Weak

EVE.SW struggles to sustain strong margins.

ROE > 15%
-1326.73%
Net Margin ≥ 15%
0.00%
Positive Free Cash Flow
No

Key Financial Metrics

Is EVE.SW Expensive or Cheap?

P/E Ratio

EVE.SW trades at -7.04 times earnings. This suggests potential undervaluation.

-7.04

PEG Ratio

When adjusting for growth, EVE.SW's PEG of 0.04 indicates potential undervaluation.

0.04

Price to Book

The market values EvoNext Holdings S.A. at 0.96 times its book value. This may indicate undervaluation.

0.96

EV/EBITDA

Enterprise value stands at 3.32 times EBITDA. This is generally considered low.

3.32

How Well Does EVE.SW Make Money?

Net Profit Margin

For every $100 in sales, EvoNext Holdings S.A. keeps $0.00 as profit after all expenses.

0.00%

Operating Margin

Core operations generate 0.00 in profit for every $100 in revenue, before interest and taxes.

0.00%

ROE

Management delivers $-13.27 in profit for every $100 of shareholder equity.

-13.27%

ROA

EvoNext Holdings S.A. generates $-12.01 in profit for every $100 in assets, demonstrating efficient asset deployment.

-12.01%

Following the Money - Real Cash Generation

FCF Per Share

Each share generates $-0.14 in free cash annually.

$-0.14

FCF Yield

EVE.SW converts -17.19% of its market value into free cash.

-17.19%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-7.04

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

0.04

vs 25 benchmark

P/B Ratio

Price to book value ratio

0.96

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.00

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.00

vs 25 benchmark

Current Ratio

Current assets to current liabilities

8.34

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.13

vs 25 benchmark

ROA

Return on assets percentage

-0.12

vs 25 benchmark

ROCE

Return on capital employed

-0.14

vs 25 benchmark

How EVE.SW Stacks Against Its Sector Peers

MetricEVE.SW ValueSector AveragePerformance
P/E Ratio-7.0428.31 Better (Cheaper)
ROE-13.27%699.00% Weak
Net Margin0.00%-130884.00% (disorted) Weak
Debt/Equity0.000.34 Strong (Low Leverage)
Current Ratio8.342775.16 Strong Liquidity
ROA-12.01%-14469.00% (disorted) Weak

EVE.SW outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews EvoNext Holdings S.A.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-100.00%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

102.06%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

92.64%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ